What Happened?
Shares of insulin delivery company Insulet Corporation (NASDAQ: PODD) fell 20.5% in the afternoon session after the company reported strong second-quarter results that were overshadowed by a weaker-than-expected revenue forecast for the upcoming quarter.
The company reported second-quarter revenue of $801.7 million, a 23.5% year-over-year increase that beat Wall Street's expectations. Adjusted earnings per share of $1.66 also came in 14.3% above analysts' consensus estimates, signaling strong current performance.
However, investor optimism was dampened by the company's guidance for the third quarter. Insulet projected revenue of $833.4 million, which fell short of the $847.3 million analysts had anticipated. The disappointing outlook prompted a significant sell-off, as investors weighed the near-term growth concerns against the solid quarterly performance.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Insulet? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Insulet’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. But moves this big are rare even for Insulet and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock gained 6.8% on the news that comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Insulet is down 52.7% since the beginning of the year, and at $133.94 per share, it is trading 62% below its 52-week high of $352.82 from September 2025. Investors who bought $1,000 worth of Insulet’s shares 5 years ago would now be looking at only $477.60.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
